DRG2 supports the growth of primary tumors and metastases of melanoma by enhancing VEGF-A expression.
Nal Ae YoonSe Jin JungSeong Hee ChoiJin Hyun RyuMuralidharan ManiUnn Hwa LeeMai-Tram VoDo Yong JeonSu Wol ChungByung Ju LeeYoung Wha KohSoon Eun ParkYong Joon ShinSang Soo KangWha Ja ChoHee Jeong ChaJeong Woo ParkPublished in: The FEBS journal (2019)
Malignant metastatic melanoma (MM) is the most lethal of all skin cancers, but detailed mechanisms for regulation of melanoma metastasis are not fully understood. Here, we demonstrated that developmentally regulated GTP-binding protein 2 (DRG2) is required for the growth of primary tumors and for metastasis. DRG2 expression was significantly increased in MM compared with primary melanoma (PM) and dysplastic nevi. A correlation between DRG2 expression and poor disease-specific survival in melanoma patients was also identified. Furthermore, inhibition of DRG2 suppressed the binding of Hypoxia-inducible factor 1α to the VEGF-A promoter region, expression of vascular endothelial growth factor (VEGF)-A, and formation of endothelial cell tubes. In experimental mice, DRG2 depletion inhibited the growth of PM and lung metastases and increased survival. These results identify DRG2 as a critical regulator of VEGF-A expression and of growth of PMs and lung metastases.
Keyphrases
- vascular endothelial growth factor
- binding protein
- poor prognosis
- endothelial cells
- transcription factor
- gene expression
- end stage renal disease
- air pollution
- newly diagnosed
- ejection fraction
- particulate matter
- risk assessment
- long non coding rna
- adipose tissue
- young adults
- skeletal muscle
- insulin resistance
- peritoneal dialysis
- patient reported outcomes
- soft tissue
- basal cell carcinoma